Aurinia Pharmaceuticals 3Q 2026: Revenue $83.7M, Net income $31.7M, EPS $0.23— 10-Q Summary

What happened

Aurinia Pharmaceuticals reported third-quarter 2026 revenue of $83.7 million, up 13.9% from a year earlier. Net income was $31.7 million, up 0.5%, and diluted earnings per share were $0.23, unchanged from the prior-year quarter.

Confirmed

Global impact / market context

Revenue growth came largely from higher LUPKYNIS carton sales and more prescribing in lupus nephritis, a kidney disease. Profit barely grew because costs rose alongside sales, so investors get more revenue but little extra profit per sale this quarter.

Analyst inference

Aurinia is funding a Phase 4 study called PRESERVE of about 150 patients and early work on aritinercept. Management expects selling and administrative costs to stay roughly flat while research spending rises, which can pressure future profit even as sales grow.

Analyst inference

What to watch

1. LUPKYNIS net product sales rose 12% in the quarter and 18% year to date, driven by higher carton sales and deeper penetration in the lupus nephritis market. Confirmed
2. The PRESERVE Phase 4 study plans to enroll about 150 patients at 50 U.S. sites, testing LUPKYNIS alongside three biologic therapies, which means medicines made from living cells. Proposed
3. Watch whether rising research spending on aritinercept and PRESERVE outpaces revenue growth, since management expects selling and administrative costs to stay substantially consistent. Analyst inference

Evidence

• Original source link unavailable